84 related articles for article (PubMed ID: 15251410)
1. Assembly of targeting complexes driven by a single-chain antibody.
Backer MV; Elliot J; Gaynutdinov TI; Backer JM
J Immunol Methods; 2004 Jun; 289(1-2):37-45. PubMed ID: 15251410
[TBL] [Abstract][Full Text] [Related]
2. Adapter protein for site-specific conjugation of payloads for targeted drug delivery.
Backer MV; Gaynutdinov TI; Patel V; Jehning BT; Myshkin E; Backer JM
Bioconjug Chem; 2004; 15(5):1021-9. PubMed ID: 15366955
[TBL] [Abstract][Full Text] [Related]
3. An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery.
Asai T; Wims LA; Morrison SL
J Immunol Methods; 2005 Apr; 299(1-2):63-76. PubMed ID: 15914191
[TBL] [Abstract][Full Text] [Related]
4. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor.
Blankenberg FG; Mandl S; Cao YA; O'Connell-Rodwell C; Contag C; Mari C; Gaynutdinov TI; Vanderheyden JL; Backer MV; Backer JM
J Nucl Med; 2004 Aug; 45(8):1373-80. PubMed ID: 15299064
[TBL] [Abstract][Full Text] [Related]
5. Self-assembled "dock and lock" system for linking payloads to targeting proteins.
Backer MV; Patel V; Jehning BT; Backer JM
Bioconjug Chem; 2006; 17(4):912-9. PubMed ID: 16848397
[TBL] [Abstract][Full Text] [Related]
6. Novel highly efficient intrabody mediates complete inhibition of cell surface expression of the human vascular endothelial growth factor receptor-2 (VEGFR-2/KDR).
Böldicke T; Weber H; Mueller PP; Barleon B; Bernal M
J Immunol Methods; 2005 May; 300(1-2):146-59. PubMed ID: 15946674
[TBL] [Abstract][Full Text] [Related]
7. [Construction and expression of single chain Fv gene against domain II of human VEGF receptor II].
Li R; Xiong DS; Shao XF; Xu YF; Liu J; Zhu ZP; Yang CZ
Sheng Wu Gong Cheng Xue Bao; 2004 Mar; 20(2):187-91. PubMed ID: 15969106
[TBL] [Abstract][Full Text] [Related]
8. Self-assembled ternary complexes of plasmid DNA, low molecular weight polyethylenimine and targeting peptide for nonviral gene delivery into neurons.
Zeng J; Wang X; Wang S
Biomaterials; 2007 Mar; 28(7):1443-51. PubMed ID: 17156837
[TBL] [Abstract][Full Text] [Related]
9. Targeting human cancer cells with VEGF receptor-2-directed liposomes.
Rubio Demirovic A; Marty C; Console S; Zeisberger SM; Ruch C; Jaussi R; Schwendener RA; Ballmer-Hofer K
Oncol Rep; 2005 Feb; 13(2):319-24. PubMed ID: 15643518
[TBL] [Abstract][Full Text] [Related]
10. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies.
Bocci G; Man S; Green SK; Francia G; Ebos JM; du Manoir JM; Weinerman A; Emmenegger U; Ma L; Thorpe P; Davidoff A; Huber J; Hicklin DJ; Kerbel RS
Cancer Res; 2004 Sep; 64(18):6616-25. PubMed ID: 15374976
[TBL] [Abstract][Full Text] [Related]
11. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: potential advantages over antibodies expressed within the intracellular environment (Intrabody).
Heng BC; Cao T
Med Hypotheses; 2005; 64(6):1105-8. PubMed ID: 15823695
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of scFv fragment reactivity with target antigens in binding assays following mixing with anti-tag monoclonal antibodies.
Wang X; Campoli M; Ko E; Luo W; Ferrone S
J Immunol Methods; 2004 Nov; 294(1-2):23-35. PubMed ID: 15604013
[TBL] [Abstract][Full Text] [Related]
13. Cysteine-containing fusion tag for site-specific conjugation of therapeutic and imaging agents to targeting proteins.
Backer MV; Levashova Z; Levenson R; Blankenberg FG; Backer JM
Methods Mol Biol; 2008; 494():275-94. PubMed ID: 18726580
[TBL] [Abstract][Full Text] [Related]
14. Single chain Fv: a ligand in receptor-mediated gene delivery.
Gupta S; Eastman J; Silski C; Ferkol T; Davis PB
Gene Ther; 2001 Apr; 8(8):586-92. PubMed ID: 11320404
[TBL] [Abstract][Full Text] [Related]
15. Production of neutralizing monoclonal antibody against human vascular endothelial growth factor receptor II.
Li R; Xiong DS; Shao XF; Liu J; Xu YF; Xu YS; Liu HZ; Zhu ZP; Yang CZ
Acta Pharmacol Sin; 2004 Oct; 25(10):1292-8. PubMed ID: 15456530
[TBL] [Abstract][Full Text] [Related]
16. Hapten-directed targeting to single-chain antibody receptors.
Cheng TL; Liao KW; Tzou SC; Cheng CM; Chen BM; Roffler SR
Cancer Gene Ther; 2004 May; 11(5):380-8. PubMed ID: 15044963
[TBL] [Abstract][Full Text] [Related]
17. Selection and characterization of an internalizing epidermal-growth-factor-receptor antibody.
Zhao X; Dai W; Cao L; Zhu H; Yu Y; Ye Q; Wang M; Dai W; Lei P; Shen G
Biotechnol Appl Biochem; 2007 Jan; 46(Pt 1):27-33. PubMed ID: 16886908
[TBL] [Abstract][Full Text] [Related]
18. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer.
Camp ER; Yang A; Liu W; Fan F; Somcio R; Hicklin DJ; Ellis LM
Clin Cancer Res; 2006 Apr; 12(8):2628-33. PubMed ID: 16638876
[TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone-related protein (107-139) increases human osteoblastic cell survival by activation of vascular endothelial growth factor receptor-2.
Alonso V; de Gortázar AR; Ardura JA; Andrade-Zapata I; Alvarez-Arroyo MV; Esbrit P
J Cell Physiol; 2008 Dec; 217(3):717-27. PubMed ID: 18651620
[TBL] [Abstract][Full Text] [Related]
20. Direct in vivo intracellular selection of conformation-sensitive antibody domains targeting Alzheimer's amyloid-beta oligomers.
Meli G; Visintin M; Cannistraci I; Cattaneo A
J Mol Biol; 2009 Apr; 387(3):584-606. PubMed ID: 19361429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
